Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Middle East Health Journal.
Press releases published on April 8, 2025
The Dealmakers Successfully Host High-Impact Investors Roundtable at DMCC Dubai
EIN Presswire
·
April 8, 2025
With the support of DMCC and Chairman Ahmed Bin Sulayem, global investors and innovators gathered to drive the future of sustainable business and investment. DUBAI, UNITED ARAB EMIRATES, April 8, 2025 /EINPresswire.com/ -- The Dealmakers proudly …
Electe Joins the World Wide Web Consortium as a AI B2B Go-to-Market Leader
EIN Presswire
·
April 8, 2025
Italian AI analytics platform becomes W3C member to influence data interoperability and privacy standards for small and medium-sized enterprises MILANO, MI, ITALY, April 8, 2025 /EINPresswire.com/ -- Electe, an Italian company leading in AI-based data …
5G, Aethra Telecommunications-Fastweb Partnership Strengthens, with Focus on Ease of Installation and Customization
EIN Presswire
·
April 8, 2025
MISSISSAUGA, ONTARIO, CANADA, April 8, 2025 /EINPresswire.com/ -- A TLC, the commercial brand of Aethra Telecommunications, has been confirmed as a vendor by the telco for services aimed at the business sector. The new 5G Outdoor Unit WNRQQ-108 is a …
First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients
GlobeNewswire
·
April 8, 2025
LA JOLLA, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced enrollment of the …
Tevogen Bio CIO and Head of Tevogen.AI Presented at AI x Bio Philly Event Showcasing Philly’s Leading AI Biotechs
GlobeNewswire
·
April 8, 2025
WARREN, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a healthcare company with dedicated efforts in immunotherapy and artificial intelligence, today announced that Mittul Mehta, Chief …
Serina Therapeutics Secures $5 Million in Funding to Support Advancement of SER-252 into Clinical Development in Advanced Parkinson's Disease
GlobeNewswire
·
April 8, 2025
HUNTSVILLE, Ala., April 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the closing of a $ …
National Minority Quality Forum Announces 2025 National Minority Health Month Theme: “Health Unlocked: Access, Alignment, Action”
GlobeNewswire
·
April 8, 2025
Washington, D.C., April 08, 2025 (GLOBE NEWSWIRE) -- The National Minority Quality Forum (NMQF) proudly announces the 2025 theme for National Minority Health Month: “Health Unlocked: Access, Alignment, Action.” This year’s theme recognizes the evolving …
Myriad Genetics Announces Inducement Awards
GlobeNewswire
·
April 8, 2025
SALT LAKE CITY, April 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today that in connection with the hiring of Mr. Donnelly as chief commercial officer, …
AMN Healthcare to Hold First Quarter 2025 Earnings Conference Call on Thursday, May 8, 2025
GlobeNewswire
·
April 8, 2025
DALLAS, April 08, 2025 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), has scheduled a conference call to discuss its first quarter 2025 financial results and second quarter 2025 outlook on Thursday, May 8, 2025, at 5:00 p.m. Eastern Time. …
ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 of 2025
GlobeNewswire
·
April 8, 2025
PORTLAND, Maine, April 08, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the …
Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer
GlobeNewswire
·
April 8, 2025
SAN DIEGO, April 08, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases …
Clover Health to Report First Quarter 2025 Financial Results on May 6, 2025
GlobeNewswire
·
April 8, 2025
WILMINGTON, Del., April 08, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that it will report first quarter 2025 financial results after market close on Tuesday, May 6 …
NeOnc Technologies Announces Near Completion of Phase I Enrollment for NEO212 Brain Cancer Therapy
GlobeNewswire
·
April 8, 2025
CALABASAS, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, today announced that …
Vincerx Pharma Announces Termination of Letter of Intent and Board Authorization to Pursue Wind-Down Activities
GlobeNewswire
·
April 8, 2025
SAN MATEO, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced that it has terminated the previously announced non-binding Letter of Intent (LOI) with Global Digital Holdings Inc., conducting business as QumulusAI …
Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting
GlobeNewswire
·
April 8, 2025
Oral Presentation Features Phase 3 Data Showing Rapid Recovery and Durable Benefit of Tanruprubart (formerly ANX005) on Clinically Meaningful Measures across Multiple Stages of GBS Disease Education Campaign for Healthcare Providers called Move GBS Forward …
Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update
GlobeNewswire
·
April 8, 2025
NX-5948 assigned the nonproprietary name “bexobrutideg” U.S. FDA Orphan Drug Designation granted to bexobrutideg for the treatment of Waldenström macroglobulinemia Achieved $7M in milestones and a $15M license extension fee from ongoing collaboration with …
BON Announces Unlocking Broccoli's Nutritional Power: Advanced Delivery System for Glucoraphanin Activation
GlobeNewswire
·
April 8, 2025
XI’AN, China, April 08, 2025 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or "the Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, announced our biotech innovation addresses …
Major Medicaid and ACA Marketplace changes could be coming: What consumers need to know now
GlobeNewswire
·
April 8, 2025
Minneapolis, MN, April 08, 2025 (GLOBE NEWSWIRE) -- Millions of people who rely on Medicaid and ACA Marketplace coverage (Obamacare) could be impacted by sweeping federal policy changes under consideration. Healthinsurance.org is closely tracking these …
Avadel Pharmaceuticals Provides Update at Needham Virtual Healthcare Conference
GlobeNewswire
·
April 8, 2025
DUBLIN, April 08, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today presented at the 24th Annual Needham Virtual Healthcare Conference. The Company …
Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis
GlobeNewswire
·
April 8, 2025
Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis Results from the HERCULES phase 3 study showed delay in disability progression in people living with non-relapsing secondary progressive …